Harmony Biosciences Holdings Inc
Research Harmony Biosciences Holdings Inc (HRMY) on Bullrun: valuation model: 7.5% undervalued, market cap USD 2.22B, P/E 12.4. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHRMY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal7.5% undervalued
- Market capUSD 2.22B
- P/E12.4
- Financial periodQ2 2026
- RevenueUSD 261.28M
- Net incomeUSD 75.43M
- Free cash flowUSD 92.43M
- Gross margin75.8%
Valuation Snapshot
Bullrun's latest valuation model marks Harmony Biosciences Holdings Inc as 7.5% undervalued; latest market cap is USD 2.22B; P/E is 12.4.
Peer valuation comparison
Latest P/E is 12.39x versus a Healthcare sector median of 24.6x (49.6% below).
Latest P/E is 12.39x versus a United States median of 23.85x (48.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 868.45M | USD 158.69M | USD 347.89M | 77.2% | 2.71 | USD 752.50M | USD 163.66M | USD 870.22M |
| FY2024 | USD 714.73M | USD 145.49M | USD 218.67M | 78.1% | 2.51 | USD 453.00M | USD 179.27M | USD 659.16M |
| FY2023 | USD 582.02M | USD 128.85M | USD 219.08M | 79.2% | 2.13 | USD 311.66M | USD 193.57M | USD 466.99M |
| FY2022 | USD 437.86M | USD 181.47M | USD 144.29M | 80.9% | 2.97 | USD 243.78M | USD 191.65M | USD 402.84M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 2.22B | 12.4 | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.16B | 13.8 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.97B | 13.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.89B | 13.1 | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.27B | 21.6 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.51B | 73.5 | n/a | n/a |
About Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS);
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Harmony Biosciences Holdings Inc overvalued or undervalued?
Bullrun's valuation model currently marks Harmony Biosciences Holdings Inc as 7.5% undervalued.
What is Harmony Biosciences Holdings Inc's market cap?
Harmony Biosciences Holdings Inc's market capitalization is USD 2.22B.
What is Harmony Biosciences Holdings Inc's P/E ratio?
Harmony Biosciences Holdings Inc's price-to-earnings (P/E) ratio is 12.4.
What does Harmony Biosciences Holdings Inc do?
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.